Tumor Immunology

On this page

Tumor Antigens - Cancer's ID Tags

  • Molecules on tumor cells recognized by the immune system (T cells, antibodies).
  • Key to immunotherapy & diagnostics.

Types of Tumor Antigens:

  • Tumor-Specific Antigens (TSAs):
    • Exclusively on tumor cells.
    • Arise from mutations (e.g., mutated p53, RAS) or viral oncogenes (e.g., HPV E6/E7).
    • Ideal targets for therapy.
  • Tumor-Associated Antigens (TAAs):
    • Also on normal cells, but overexpressed or aberrantly expressed on tumors.
    • Examples:
      • Oncofetal antigens: AFP (liver cancer), CEA (colon cancer).
      • Differentiation antigens: PSA (prostate cancer), MART-1 (melanoma).
      • Overexpressed self-proteins: HER2/neu (breast cancer).

⭐ CEA (Carcinoembryonic Antigen) is a classic TAA used primarily for monitoring colorectal cancer recurrence, not for initial diagnosis due to low specificity/sensitivity.

📌 Mnemonic: Tumor Specific = Solely on Tumors; Tumor Associated = Also on normal, but Abnormal on Tumors.

Immune Surveillance - Body's Cancer Cops

  • Natural defense: Recognizes & eliminates nascent transformed cells.
  • Mediated by both innate & adaptive immunity.
  • Key Effector Cells:
    • Innate:
      • Natural Killer (NK) cells: Target cells with ↓MHC-I or stress ligands (e.g., MICA/B). Release perforin, granzymes.
      • M1 Macrophages: Phagocytosis, release TNF-α, NO.
    • Adaptive:
      • Cytotoxic T Lymphocytes (CTLs/CD8+ T cells): Recognize tumor antigens on MHC-I. Induce apoptosis (perforin/granzymes, Fas-FasL).
      • Helper T cells (Th1/CD4+ T cells): Secrete IFN-γ (activates CTLs, Mφ), TNF-α.

⭐ IFN-γ, produced mainly by Th1 cells and NK cells, is pivotal for anti-tumor immunity by activating macrophages and enhancing CTL differentiation and killing.

  • Evidence: ↑cancer incidence in immunosuppressed individuals (e.g., AIDS, transplant recipients).

Loading diagram…

Tumor Evasion - Cancer's Escape Artistry

  • ↓ MHC-I Expression:
    • Tumor cells evade CTL recognition.
    • Mutations in TAP, β2-microglobulin.
  • Antigen Masking/Shedding:
    • Glycocalyx (sialomucins) hides antigens.
    • Shed antigens neutralize antibodies.
  • Immunosuppressive Microenvironment:
    • Secretion: TGF-β, IL-10.
    • Recruitment: Tregs, MDSCs.
    • Checkpoint Ligands:
      • PD-L1 (tumor) binds PD-1 (T-cell) → T-cell exhaustion.
      • CTLA-4 (T-cell) binds B7 ligands (tumor/APCs) → ↓ T-cell activation.
  • Induce T-cell Apoptosis:
    • Tumor FasL binds Fas on T-cells → apoptosis.
  • Lack of Co-stimulation:
    • Absent B7 (CD80/CD86) on tumor cells → T-cell anergy.
  • Antigenic Variation:
    • Immune selection of antigen-negative variants.

⭐ PD-L1 expression on tumor cells binds PD-1 on T-cells, causing T-cell exhaustion. This is a key immune escape targeted by checkpoint inhibitors (e.g., Pembrolizumab).

Cancer Immunotherapy - Boosting The Defense

  • Principle: Augmenting patient's immune system to target and destroy cancer cells.
  • Key Strategies:
    • Immune Checkpoint Inhibitors (ICIs):
      • Block T-cell inhibitory signals (PD-1/PD-L1, CTLA-4).
      • E.g., Pembrolizumab (anti-PD-1), Ipilimumab (anti-CTLA-4).
      • Unleashes T-cell anti-tumor response.
    • Adoptive Cell Therapy (ACT):
      • CAR T-cells: T-cells engineered with Chimeric Antigen Receptors (e.g., anti-CD19 for B-cell malignancies).
      • TILs: Ex vivo expanded Tumor-Infiltrating Lymphocytes.
    • Cancer Vaccines: E.g., Sipuleucel-T (prostate cancer).
    • Oncolytic Viruses: E.g., T-VEC (melanoma).
    • Cytokines: Non-specific immunostimulants (IL-2, IFN-α).

⭐ Immune Checkpoint Inhibitors (ICIs) targeting PD-1/PD-L1 (e.g., Pembrolizumab) have revolutionized treatment for melanoma, NSCLC, and renal cell carcinoma.

Loading diagram…

High‑Yield Points - ⚡ Biggest Takeaways

  • Tumor Antigens: Include Tumor-Specific Antigens (TSAs) and Tumor-Associated Antigens (TAAs).
  • Immune Surveillance: Primarily mediated by Cytotoxic T Lymphocytes (CTLs) and NK cells.
  • Tumor Evasion Strategies: Include ↓MHC-I expression, PD-L1 upregulation, and immunosuppressive cytokines.
  • Immune Checkpoint Blockade: Anti-PD-1/PD-L1 and Anti-CTLA-4 therapies reinvigorate T-cell responses.
  • Adoptive Cell Therapy: CAR T-cells are engineered to recognize and kill cancer cells.
  • Chronic Inflammation: Can promote tumorigenesis by creating a favorable microenvironment_

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Tumor Immunology

  1. 1. Isolated aPTT prolongation associated with thrombosis rather than bleeding is typically seen with which of the following?

    • A. Coagulation factor VII deficiency
    • B. Antiphospholipid antibodies
    • C. Vitamin K deficiency
    • D. Von Willebrand's disease
    Show answer

    Answer: B. Antiphospholipid antibodies

    Antiphospholipid antibodies, particularly lupus anticoagulant, prolong phospholipid-dependent aPTT assays and are associated with thrombosis rather than bleeding. Coagulation factor VII deficiency prolongs PT rather than aPTT. Vitamin K deficiency prolongs PT first and may prolong both PT and aPTT when severe. Von Willebrand’s disease may prolong aPTT through reduced factor VIII but typically causes mucocutaneous bleeding rather than thrombosis.

  2. 2. Which immunoglobulin is most efficient at fixing C1q in the classical complement pathway?

    • A. IgM
    • B. IgG
    • C. IgE
    • D. IgA
    Show answer

    Answer: A. IgM

    IgM - IgM is most efficient at fixing C1q because its pentameric structure presents multiple Fc regions for complement binding after antigen attachment. - Antigen-bound IgM undergoes a conformational change that exposes its Fc-region C1q-binding sites, efficiently initiating the classical complement pathway. IgG - IgG can activate the classical complement pathway, but two or more molecules must be positioned closely on an antigen-bearing surface for effective C1q binding. - Compared with pentameric IgM, monomeric IgG is less efficient because its Fc regions bind C1q mainly when clustered in antigen–antibody complexes. IgE - IgE is primarily involved in type I hypersensitivity and defense against parasites through Fc-receptor-mediated activation of mast cells and basophils. - IgE does not efficiently activate the classical complement pathway, so it is not an effective immunoglobulin for fixing C1q. IgA - IgA primarily provides mucosal immunity, where it neutralizes pathogens and toxins at epithelial surfaces rather than efficiently activating classical complement. - Although IgA may weakly activate the alternative pathway, it is not effective at fixing C1q in the classical pathway.

  3. 3. Which DNA lesion is characteristically produced directly by UVB radiation?

    • A. Pyrimidine dimers
    • B. Interstrand DNA crosslinks
    • C. DNA double-strand breaks
    • D. Bulky guanine adducts
    Show answer

    Answer: A. Pyrimidine dimers

    Pyrimidine dimers are characteristic direct UVB photolesions formed between adjacent pyrimidines on the same DNA strand. Interstrand DNA crosslinks join opposing DNA strands and are classically produced by crosslinking agents rather than representing the characteristic UVB photolesion. DNA double-strand breaks are characteristic of ionising radiation injury rather than the direct lesion tested here. Bulky guanine adducts are associated with chemical carcinogens such as aflatoxin B1 rather than the characteristic direct UVB photolesion.

  4. 4. Therapeutic uses of prostaglandin E1 and its analogues include all of the following EXCEPT:

    • A. Treatment of erectile dysfunction
    • B. Maintenance of ductal patency
    • C. Medical termination of pregnancy
    • D. Primary pulmonary hypertension
    Show answer

    Answer: D. Primary pulmonary hypertension

    Primary pulmonary hypertension - Although PGE1 is a vasodilator, it is not the standard prostaglandin therapy for primary pulmonary hypertension; that role is associated with PGI2 drugs. - Epoprostenol, with analogues such as treprostinil and iloprost, is used for pulmonary vascular disease, making primary pulmonary hypertension the exception. Treatment of erectile dysfunction - Alprostadil (PGE1) causes local penile vasodilation when administered intracavernosally or intraurethrally, producing an erection in patients with erectile dysfunction. - Therefore, impotence is a recognized therapeutic use of PGE1 and does not represent the exception in this question. Maintenance of ductal patency - Intravenous PGE1 (alprostadil) maintains ductal patency in neonates with ductus-dependent circulation, including some cases of transposition of the great arteries. - This use preserves systemic or pulmonary blood flow temporarily while definitive intervention is arranged, so it is a valid therapeutic application. Medical termination of pregnancy - Misoprostol, a synthetic PGE1 analogue, promotes uterine contractions and cervical ripening and is used with mifepristone for medical termination of pregnancy. - Thus, medical termination of pregnancy is associated with the PGE1 analogue class and is not the incorrect option.

  5. 5. What is the immunological rationale for combined LAG-3 and PD-1 blockade in melanoma?

    • A. Reversal of nonredundant T-cell inhibition
    • B. Depletion of intratumoral regulatory T cells
    • C. Restoration of tumour MHC-I expression
    • D. Enhanced Fc-mediated tumour-cell killing
    Show answer

    Answer: A. Reversal of nonredundant T-cell inhibition

    Reversal of nonredundant T-cell inhibition is the rationale: LAG-3 and PD-1 transmit distinct inhibitory signals, so combined blockade can enhance antitumour T-cell function. Enhanced Fc-mediated tumour-cell killing is not the intended mechanism because these drugs do not principally target tumour cells for antibody-mediated destruction. Depletion of intratumoral regulatory T cells is not the established rationale for this combination. Restoration of tumour MHC-I expression is not the direct mechanism of LAG-3 and PD-1 blockade.

  6. 6. What is the best marker to assess prognosis after surgery for colon carcinoma?

    • A. CEA
    • B. CA 19-9
    • C. AFP
    • D. CA-125
    Show answer

    Answer: A. CEA

    CEA - CEA is a well-established tumor marker for monitoring colorectal cancer after surgery and assessing prognosis during follow-up. - Persistently elevated or rising CEA levels after surgery may suggest residual disease or recurrence, making it the best option here. CA-125 - CA-125 is primarily associated with ovarian cancer and some other malignancies, rather than serving as a standard marker for colorectal carcinoma. - Although CA-125 may be elevated in some gastrointestinal conditions, its role in assessing postoperative colon cancer prognosis is limited and less relevant than CEA. CA 19-9 - CA 19-9 is primarily associated with pancreatic and biliary tract cancers, not specifically with colon carcinoma. - It can be elevated in some gastrointestinal malignancies, but it is not the best marker for postoperative colorectal cancer prognosis. AFP - AFP is mainly used to monitor hepatocellular carcinoma and certain germ cell tumors, rather than colorectal malignancies. - Its levels are not typically correlated with prognosis after colon cancer surgery, making it inappropriate for routine colorectal follow-up.

  7. 7. Which of the following is the most potent stimulator of Naive T-cells?

    • A. Mature DCs
    • B. Macrophages
    • C. B lymphocytes
    • D. Follicular DCs
    Show answer

    Answer: A. Mature DCs

    Mature DCs - Mature dendritic cells are the most potent APCs for activating naive T cells, owing to efficient antigen presentation and high expression of MHC-peptide complexes and CD80/CD86. - After activation by pathogens or inflammatory signals, they migrate to secondary lymphoid organs and initiate primary T-cell immune responses. Follicular DCs - Follicular dendritic cells primarily display intact antigens to B cells within germinal centers, supporting B-cell maturation, selection, and antibody production. - They lack MHC class II molecules, so they cannot directly present processed antigen to or efficiently activate naive T cells. Macrophages - Macrophages are professional APCs but are generally less effective than mature dendritic cells at activating naive T cells during primary immune responses. - They more commonly present antigen to previously activated T cells and clear pathogens, rather than initiating naive T-cell activation. B lymphocytes - B cells can function as APCs but are generally less efficient than mature dendritic cells at activating naive T cells in a primary immune response. - Their antigen presentation mainly supports helper T-cell costimulation, enabling B-cell activation, differentiation, and antibody production.

  8. 8. Which GnRH agonist is approved for advanced prostate cancer?

    • A. Goserelin
    • B. Ganirelix
    • C. Abarelix
    • D. Cetrorelix
    Show answer

    Answer: A. Goserelin

    Goserelin - Goserelin is a GnRH agonist approved for advanced prostate cancer and produces sustained suppression of gonadal hormone activity. - Initially stimulating and then desensitizing pituitary GnRH receptors decreases LH and FSH, thereby reducing testosterone production in hormone-sensitive prostate cancer. Ganirelix - Ganirelix is a GnRH antagonist, not an agonist, so it does not match the drug class requested. - It is primarily used in assisted reproductive technology to prevent premature LH surges, rather than for advanced prostate cancer. Abarelix - Abarelix is a GnRH antagonist, directly blocking GnRH receptors rather than initially stimulating and subsequently desensitizing them. - Although it was approved for advanced prostate cancer, its antagonist mechanism means it does not satisfy the question asking for a GnRH agonist. Cetrorelix - Cetrorelix is a GnRH antagonist, not an agonist, and therefore does not produce the requested agonist-mediated pituitary desensitization. - It is primarily used in assisted reproductive technology to prevent premature ovulation, not as treatment for advanced prostate cancer.

  9. 9. Which of the following conditions is least associated with tumor suppressor genes?

    • A. Retinoblastoma
    • B. Hereditary breast cancer
    • C. Neurofibromatosis
    • D. Acute myeloid leukemia
    Show answer

    Answer: D. Acute myeloid leukemia

    Acute myeloid leukemia is least classically associated with tumor-suppressor gene defects among these conditions. Its pathogenesis commonly involves acquired alterations in signaling and transcription, although tumor-suppressor abnormalities can occur. Retinoblastoma is classically associated with inactivation of the RB1 tumor suppressor gene. Hereditary breast cancer has recognized associations with the BRCA1 and BRCA2 tumor suppressor genes, which participate in DNA repair. Neurofibromatosis involves defects in the NF1 or NF2 tumor suppressor genes. These established tumor-suppressor associations make the other conditions less suitable answers.

  10. 10. In the absence of maternal vaccination during pregnancy, congenital passive immunity is generally inadequate against which infection?

    • A. Epidemic parotitis
    • B. Rubella
    • C. Measles
    • D. Pertussis
    Show answer

    Answer: D. Pertussis

    Pertussis is associated with inadequate congenital passive immunity in the absence of maternal vaccination during pregnancy. Maternal IgG against Bordetella pertussis crosses the placenta, but maternal antibody levels following natural infection may be insufficient to provide reliable protection to young infants. Maternal Tdap vaccination enhances this passive protection. Epidemic parotitis is not the best answer because maternal antibodies generally provide protection during early infancy. Rubella is not the best answer because transplacental maternal IgG provides passive protection after birth. Measles is not the best answer because maternal antibodies generally protect infants during the first months of life.

Flashcards: Tumor Immunology

  1. 1. Major clinical manifestations of GVHD result from the involvement of the immune system and epithelia of the skin, _____, and _____

    Show answer

    liver · intestine

  2. 2. are cytosolic complexes that recognize products of dead cells (e.g., uric acid, ATP) and trigger the activation of caspase-1.

    Show answer

    Inflammasomes

  3. 3. is a IHC marker seen with Breast carcinoma, urothelial carcinoma, salivary duct carcinoma and choriocarcinoma

    Show answer

    GATA3

  4. 4. In the setting of chronic inflammation, macrophages can be activated to M1 macrophages by stimulation from _____ cells, resulting in a _____ phenotype

    Show answer

    Th1 · proinflammatory

  5. 5. Biopsy for IgG4 disease will demonstrate dense infiltrate

    Show answer

    lymphoplasmacytic

  6. 6. Which blood type does not have any group antigens on RBC surfaces?

    Show answer

    Type O

  7. 7. LE cell is a phagocytic _____ or _____ that has engulfed the denatured nucleus of an injured cell

    Show answer

    neutrophil · macrophage

  8. 8. --- Do with heme ---\nType II Hypersensitivity Disorders - Cytotoxic:\nTransfusion Reaction\n- Antibody against _____\n- IgM isohemagglutinins formed naturally in response to bacterial flora cause opsonization and complement activation\n- Leads to hemolysis\nHemolytic Disease of the Newborn (Erythroblastosis fetalis)\nAntibody = _____\n- Formed in _____ mother carrying _____ child\n- First pregnancy _____ (doesn't have to be viable pregnancy)\n- Antibody crosses placenta and injures subsequent fetuses\n- Prevent with _____ (anti-Rh, binds fetal red cells and prevents mothers immune system from reacting)\nABO blood typing and screening for other preformed Abs; always done in case of transplants.\nUniversal donor: type _____\nUniversal recipient: type _____\n(Ex) Type A can donate to _____ and _____. Type A can receive donations from _____ and _____.\n- Anti-B antibodies prevent donation from type B and type AB.\nHLA Typing - Microcytotoxicity test\nTests for MHC _____\nTest hundreds of different haplotypes to find a potential match.\nCells recognized by antibody will be attacked by complement and thus become leaky and take up dye.\nHLA Typing - Mixed lymphocyte reaction\nTests for MHC class _____\nTake donor cells and irradiate them (prevent proliferation). Irradiated donor cells are mixed with recipient cells to see if proliferation occurs.\nHigher radioactivity (thymidine) signifies _____ compatibility.

    Show answer

    ABO blood glycoproteins · Anti-RhD+ IgG · Rh- · Rh+ · sensitizes · RhoGAM · O · AB · type A · type AB · type A · type O · class I (HLA-A, HLA-B) · II (HLA-DR) · lower

  9. 9. _____ cells are _____ cells characterized by the accumulation of multiple _____

    Show answer

    Mott · plasma · Russell bodies

  10. 10. _____ is caused by a defect in the _____ gene

    Show answer

    X-linked (Bruton) agammaglobulinemia · BTK

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF